Extended Data Fig. 2: RBD-specific functional antibody responses to SARS-CoV-2 variants.
From: Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
![Extended Data Fig. 2](https://cdn.statically.io/img/media.springernature.com/full/springer-static/esm/art%3A10.1038%2Fs41586-021-03681-2/MediaObjects/41586_2021_3681_Fig6_ESM.jpg)
Top, RBD-specific ADCP, ADNP and ADCD against WA1/2020 (D614G), B.1.1.7 and B.1.351. LD, low dose; HD, high dose; PL, placebo on day 71. Filled circles, high dose–placebo; open circles, high dose–high dose; filled triangles, low dose–placebo; open triangles, low dose–low dose. Bottom, RBD-specific isotype (IgG1, IgG3, IgA, IgM) (red) and FcγR2a, FcγR2b, FcγR3a (blue) binding against WA1/2020 (D614G), B.1.1.7, B.1.351 on day 71. n = 20 independent samples from Ad26.COV2.S vaccine recipients.